{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T17:15:43Z","timestamp":1780766143360,"version":"3.54.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.3816\/cbc.2001.n.016","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:04:27Z","timestamp":1221080667000},"page":"113-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Review of Vinorelbine in the Treatment of Breast Cancer"],"prefix":"10.3816","volume":"2","author":[{"given":"Gabriel H.","family":"Domenech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2001.n.016_bib1","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.1999.17.10.3082","article-title":"Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer","volume":"17","author":"Leung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib2","series-title":"Navelbine package insert","year":"1996"},{"key":"10.3816\/CBC.2001.n.016_bib3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ajhp\/52.12.1287","article-title":"Vinorelbine: a novel vinca alkaloid","volume":"52","author":"Toso","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"10.3816\/CBC.2001.n.016_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0006-2952(99)00190-2","article-title":"Differential in vitro association of vinca alkaloid-induced tubulin spiral filaments into aggregated spirals","volume":"58","author":"Verdier-Pinard","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"suppl 4","key":"10.3816\/CBC.2001.n.016_bib5","first-page":"9","article-title":"Biochemical effects of Navelbine on tubulin and associated proteins","volume":"16","author":"Fellous","year":"1989","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.2910460220","article-title":"Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules","volume":"46","author":"Binet","year":"1990","journal-title":"Int J Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib7","first-page":"110a","article-title":"Pharmacokinetic\/pharmacodynamic relationships of IV and oral vinorelbine (Navelbine\u00ae) in phase I patients","volume":"20","author":"Variol","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib8","first-page":"110a","article-title":"Docetaxel and vinorelbine: sequence-dependent pharmacokinetic interactions and influences on neutrophils number at nadir","volume":"20","author":"Airoldi","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","article-title":"Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy","volume":"11","author":"Fumoleau","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1994.12.2.336","article-title":"Vinorelbine as first-line chemotherapy for metastatic breast carcinoma","volume":"12","author":"Romero","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000421-199510000-00006","article-title":"Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience","volume":"18","author":"Bruno","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/bjc.1994.435","article-title":"A phase II, multicentre, UK study of vinorelbine in advanced breast cancer","volume":"70","author":"Twelves","year":"1994","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib13","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.annonc.a059019","article-title":"Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy","volume":"5","author":"Garcia-Conde","year":"1994","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2001.n.016_bib14","first-page":"33","article-title":"Phase-II study of Navelbine in advanced breast cancer","volume":"16","author":"Canobbio","year":"1989","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1008364222793","article-title":"Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older","volume":"10","author":"Vogel","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib16","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1995.13.11.2722","article-title":"Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer","volume":"13","author":"Weber","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib17","first-page":"96","article-title":"Vinorelbine (VRL) as palliative treatment in elderly patients (PTS) with metastatic breast cancer","volume":"46","author":"Buonadonna","year":"1997","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib18","first-page":"61b","article-title":"Single agent vinorelbine in elderly patients with advanced breast cancer: a multicenter phase II study","volume":"20","author":"Rossi","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib19","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.1994.12.10.2094","article-title":"Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study","volume":"12","author":"Gasparini","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.1997.15.4.1395","article-title":"Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer","volume":"15","author":"Livingston","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.annonc.a058873","article-title":"Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer","volume":"5","author":"Degardin","year":"1994","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib22","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib23","first-page":"146","article-title":"Vinorelbine (NVB) activity in heavily pretreated breast cancer (BC) patients (pts)","volume":"15","author":"Alvarez","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib24","first-page":"125","article-title":"Vinorelbine (VNR) in weekly schedule with G-CSF in patients with advanced breast cancer (ABC)","volume":"15","author":"Ranuzzi","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0959-8049(99)00219-1","article-title":"Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer","volume":"36","author":"Udom","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib26","first-page":"89","article-title":"Results of weekly vinorelbine (VNB) after failure with taxanes in advanced breast cancer (ABC)","volume":"57","author":"Zelek","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1006390700480","article-title":"Weekly schedule of vinorelbine in pretreated breast cancer patients","volume":"59","author":"Nistico","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.4-1-17","article-title":"Monotherapy of metastatic breast cancer: a review of newer agents","volume":"4","author":"Vogel","year":"1999","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2001.n.016_bib29","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dosefinding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","article-title":"Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic","volume":"7","author":"Gehl","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1091::AID-CNCR12>3.0.CO;2-A","article-title":"A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma","volume":"85","author":"Blajman","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib32","first-page":"85","article-title":"Vinorelbine (VNB) containing regimens in three different schedules for the treatment of advanced breast cancer (ABC)","volume":"13","author":"Coppola","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib33","first-page":"197a","article-title":"Phase II study of IV Navelbine (NVB) and doxorubicin (DOX) in previously untreated advanced breast cancer (ABC)","volume":"16","author":"Vorobiof","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.1994.12.9.1764","article-title":"Phase II trial of vinorelbine\/doxorubicin as first-line therapy of advanced breast cancer","volume":"12","author":"Spielmann","year":"1994","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.3816\/CBC.2001.n.016_bib35","first-page":"55","article-title":"Combined doxorubicin\/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer","volume":"22","author":"Hochster","year":"1995","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib36","first-page":"25","article-title":"Navelbine (NVB) doxorubicin (DX) combination (D1-D8) in advanced breast carcinoma previously untreated","volume":"7","author":"Firat","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib37","first-page":"287","article-title":"Navelbine (NVB) 25 mg\/m2 and doxorubicin (DX) 25 mg\/m2, on day 1 & 8 for the treatment of metastatic breast cancer","volume":"41","author":"Hegg","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib38","first-page":"286","article-title":"A multicenter phase II study of navelbine (NVB) and doxorubicin (DOX) as first line chemotherapy in advanced breast cancer (ABC): preliminary results","volume":"41","author":"Pawlicki","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib39","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1200\/JCO.2000.18.12.2385","article-title":"Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic\/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8","volume":"18","author":"Norris","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib40","first-page":"127a","article-title":"A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib41","first-page":"73a","article-title":"Doxorubicin (A)\/Taxol (T) versus doxorubicin\/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): a phase III study","volume":"19","author":"Biganzoli","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib42","first-page":"73a","article-title":"Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin\/paclitaxel (ET) vs epirubicin\/cyclophosphamide (EC). A study of the Ago Breast Cancer Group","volume":"19","author":"Luck","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib43","first-page":"151a","article-title":"Docetaxel (D) in combination with epirubicin (E) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC): final results","volume":"17","author":"Kerbrat","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib44","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1023\/A:1008323200102","article-title":"Phase I study of Doxil and vinorelbine in metastatic breast cancer","volume":"10","author":"Burstein","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib45","first-page":"115a","article-title":"Unexpected low efficacy of Caelyx and vinorelbine in metastatic breast cancer (MBC)","volume":"19","author":"Rimassa","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/A:1006059211817","article-title":"Epirubicin\/vinorelbine as first line therapy in metastatic breast cancer","volume":"49","author":"Baldini","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1023\/A:1008324329562","article-title":"Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer","volume":"10","author":"Nistico","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib48","first-page":"114a","article-title":"Phase II study of vinorelbine, epirubicin and cyclophosphamide (NEC) as first line chemotherapy in patients with metastatic breast cancer (MBC): preliminary results","volume":"18","author":"Braud","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib49","first-page":"115a","article-title":"A multicentric phase II trial of vinorelbine (VNB) and epirubicin (EPI) as first line chemotherapy in metastatic breast cancer (MBC). preliminary data","volume":"18","author":"Vici","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib50","first-page":"202","article-title":"[Combination of mitoxantronevinorelbine as first-line chemotherapy for metastatic breast carcinoma]","volume":"82","author":"Ferrero","year":"1995","journal-title":"Bull Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1159\/000011883","article-title":"First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study","volume":"55","author":"Llombart-Cussac","year":"1998","journal-title":"Oncology"},{"key":"10.3816\/CBC.2001.n.016_bib52","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0959-8049(01)00093-4","article-title":"Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC\/FEC in front-line therapy of metastatic breast cancer","volume":"37","author":"Namer","year":"2001","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"10.3816\/CBC.2001.n.016_bib53","first-page":"61","article-title":"Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review","volume":"22","author":"Vogel","year":"1995","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib54","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.1996.14.12.3097","article-title":"Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method","volume":"14","author":"Dieras","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008209429204","article-title":"Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden","volume":"8","author":"Nole","year":"1997","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib56","first-page":"114a","article-title":"Vinorelbine and protracted infusional 5-fluorouracil is a very active and manageable scheme for heavily pretreated advanced breast cancer patients","volume":"18","author":"Dogliotti","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008333327500","article-title":"Combination chemotherapy with navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer","volume":"11","author":"Lombardi","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib58","first-page":"113a","article-title":"First line chemotherapy for metastatic breast cancer (MBC): a regimen with a low subjective toxic burden containing vinorelbine (V), continuous infusion 5-fluorouracil (ci FU) and cisplatin (P) (ViFuP)","volume":"18","author":"Nole","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib59","first-page":"91","article-title":"A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC)","volume":"14","author":"Vogel","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib60","first-page":"109a","article-title":"Phase I\/II study of vinorelbine in combination with a weekly schedule of folinic acid and infusional 5-FU in patients with metastatic breast cancer","volume":"19","author":"Borquez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib61","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.2000.18.19.3370","article-title":"Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines","volume":"18","author":"Berruti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib62","first-page":"125","article-title":"Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC)","volume":"64","author":"Nole","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib63","first-page":"58b","article-title":"Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer","volume":"20","author":"Welt","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib64","first-page":"48b","article-title":"Vinorelbine\/capecitabine (VINOCAP) combination remission induction therapy for metastatic breast cancer (MBC)","volume":"20","author":"Domenech","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib65","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1016\/S0959-8049(99)81703-1","article-title":"Vinorelbine and paclitaxel in advanced breast cancer","volume":"35","author":"Pronzato","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib66","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.1999.17.1.74","article-title":"Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer","volume":"17","author":"Romero Acuna","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1023\/A:1008374425246","article-title":"Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure","volume":"11","author":"Martin","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000012071","article-title":"First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer","volume":"58","author":"Vici","year":"2000","journal-title":"Oncology"},{"key":"10.3816\/CBC.2001.n.016_bib69","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.1999.17.5.1407","article-title":"Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin- treated patients","volume":"17","author":"Ellis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib70","first-page":"119a","article-title":"A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC)","volume":"18","author":"De Paz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib71","first-page":"48a","article-title":"Activity of docetaxel + vinorelbine in patients with metastatic breast cancer relapsing after high-dose chemotherapy with stem cell rescue","volume":"18","author":"Bueso","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib72","first-page":"106a","article-title":"Docetaxel + vinorelbine with concurrent G-CSF support: a phase II study in stage IV breast cancer","volume":"19","author":"Gralow","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib73","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/JCO.2001.19.3.621","article-title":"Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor","volume":"19","author":"Kornek","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib74","first-page":"108a","article-title":"Docetaxel and vinorelbine every 14-days in patients with metastatic breast cancer after using anthracyclines. final results","volume":"19","author":"Gomez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib75","first-page":"112a","article-title":"Docetaxel (DOC) and Navelbine (NVB) as first line chemotherapy (CT) in advanced breast cancer (ABC). A phase II study of Hellenic Cooperative Oncology Group","volume":"19","author":"Pectasides","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1006254315174","article-title":"Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro","volume":"56","author":"Kano","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib77","first-page":"104a","article-title":"ATN (Adriamycin-Taxotere- Navelbine): a phase I-II multicentre study in first line therapy of metastatic breast cancer (MBC)","volume":"19","author":"Deplanque","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib78","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib79","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib80","first-page":"135a","article-title":"Cisplatinum and vinorelbine (CV) in metastatic breast cancer (MBC) after anthracycline failure","volume":"18","author":"Mustacchi","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/030089160008600404","article-title":"Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer","volume":"86","author":"Gunel","year":"2000","journal-title":"Tumori"},{"key":"10.3816\/CBC.2001.n.016_bib82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<134::AID-CNCR16>3.0.CO;2-3","article-title":"Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and\/or paclitaxel-containing regimens","volume":"82","author":"Ray-Coquard","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib83","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00000421-199906000-00018","article-title":"Combination cisplatinvinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer","volume":"22","author":"Shamseddine","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib84","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptorenhanced chemosensitivity using recombinant humanized antip185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib85","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1988.6.12.1811","article-title":"Cisplatin as first-line therapy for metastatic breast cancer","volume":"6","author":"Sledge","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00254257","article-title":"Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer","volume":"11","author":"Kolaric","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CBC.2001.n.016_bib87","first-page":"127a","article-title":"High complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapy","volume":"19","author":"Hurley","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib88","first-page":"794","article-title":"[Mitomycin-vinorelbine combination as second-line chemotherapy in metastatic cancer of the breast]","volume":"85","author":"Bourgeois","year":"1998","journal-title":"Bull Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib89","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000012072","article-title":"Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study","volume":"58","author":"De Placido","year":"2000","journal-title":"Oncology"},{"key":"10.3816\/CBC.2001.n.016_bib90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000227528","article-title":"Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer","volume":"53","author":"Vici","year":"1996","journal-title":"Oncology"},{"issue":"suppl","key":"10.3816\/CBC.2001.n.016_bib91","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s002800051108","article-title":"Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy","volume":"44","author":"Lobo","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CBC.2001.n.016_bib92","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.1996.14.11.2993","article-title":"Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer","volume":"14","author":"Leone","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib93","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1023\/A:1008221109364","article-title":"Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline- resistant metastatic breast cancer: a phase I-II clinical trial","volume":"9","author":"Campisi","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib94","first-page":"164a","article-title":"Second-line therapy with ifosfamide plus vinorelbine (VRB) for advanced breast cancer","volume":"16","author":"Bruno","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib95","first-page":"112a","article-title":"Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC)","volume":"18","author":"Tagliabue","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib96","first-page":"110a","article-title":"A phase II study of gemcitabine (G) and vinorelbine (V) in patients with advanced breast cancer (ABC)","volume":"19","author":"Gokmen","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib97","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1006136112585","article-title":"Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor","volume":"55","author":"Haider","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib98","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","article-title":"Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer","volume":"19","author":"Burstein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib99","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib100","first-page":"59b","article-title":"Multicenter phase II trial of weekly Navelbine plus Herceptin in chemonaive patients with HER2 positive metastatic breast carcinoma","volume":"20","author":"Jahanzeb","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib101","first-page":"114","article-title":"Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2\/neu overexpression","volume":"57","author":"Konecny","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib102","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Pegram","year":"1999","journal-title":"Oncogene"},{"issue":"suppl","key":"10.3816\/CBC.2001.n.016_bib103","first-page":"14","article-title":"Breast conservation following VEM (vinorelbine, epirubicin and methotrexate) induction chemotherapy in 89 operable breast cancers","volume":"7","author":"Van Praagh","year":"1996","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib104","first-page":"125a","article-title":"Navelbine + epirubicin + methotrexate (NEM) as neoadjuvant treatment for locally advanced breast carcinoma (LABC)","volume":"17","author":"Abrahamova","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib105","first-page":"127a","article-title":"Multidisciplinary therapy of locally advanced breast cancer (LABC) with an induction chemotherapy combination of fluorouracil, epirubicin and vinorelbine (FEN) followed by surgery and postoperative chemoradiotherapy. An ongoing phase II study","volume":"17","author":"Ardavanis","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib106","first-page":"329","article-title":"Neoadjuvant chemotherapy in operable breast cancer. High pathological response rate and survival induced by TNCF","volume":"50","author":"Cure","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2001.n.016_bib107","first-page":"135a","article-title":"Primary chemotherapy in operable or locally advanced breast cancer (OLABC) using a regimen containing vinorelbine (V), cisplatin (P) and continuous infusion of fluorouracil (FUci)","volume":"18","author":"Minchella","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib108","first-page":"143a","article-title":"Primary chemotherapy combining vinorelbine, cyclophosphamide and epirubicin (NEC) in locally advanced breast cancer (LABC): final results of a phase II study","volume":"19","author":"Braud","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib109","first-page":"707","article-title":"Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine)","volume":"22","author":"Rittenberg","year":"1995","journal-title":"Oncol Nurs Forum"},{"issue":"suppl 5","key":"10.3816\/CBC.2001.n.016_bib110","first-page":"72","article-title":"Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer","volume":"22","author":"Winer","year":"1995","journal-title":"Semin Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2001.n.016_bib111","first-page":"108","article-title":"A multicenter randomized phase II study of oral Navelbine (oNVB) versus intravenous Navelbine (iNVB) in advanced NSCLC","volume":"11","author":"Jassem","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib112","first-page":"47a","article-title":"A phase II study of oral vinorelbine (NVBo) in first line locally advanced\/metastatic breast cancer (ABC) chemotherapy. Preliminary results","volume":"20","author":"Trillet-Lenoir","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib113","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1251::AID-CNCR21>3.0.CO;2-F","article-title":"Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma","volume":"86","author":"Ibrahim","year":"1999","journal-title":"Cancer"},{"key":"10.3816\/CBC.2001.n.016_bib114","first-page":"118a","article-title":"A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer in the UK","volume":"19","author":"Leonard","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2001.n.016_bib115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00003495-200059030-00015","article-title":"Docetaxel: an update of its use in advanced breast cancer","volume":"59","author":"Figgitt","year":"2000","journal-title":"Drugs"},{"key":"10.3816\/CBC.2001.n.016_bib116","first-page":"101a","article-title":"Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)","volume":"17","author":"Henderson","year":"1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911703056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911703056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:07:45Z","timestamp":1761512865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911703056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S1526820911703056"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2001.n.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Vinorelbine in the Treatment of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2001.n.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}